Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Inclusion Criteria:

• Subjects ≥18 years of age at the time of signing informed consent

• Histologically or cytologically documented locally advanced or metastatic NSCLC,SCCHN, CRC, RCC, SCLC, PDAC, TNBC

• Progressed or was intolerant to all available therapies known to confer clinicalbenefit appropriate for the tumor type

• Adequate organ function

• At least 1 measurable lesion per RECIST 1.1

Exclusion Criteria:

• Treatment with anti-cancer therapy within 28 days or ≤5 elimination half-lives,whichever is earlier, before enrollment

• Prior treatment with EGFR-targeted bispecific T cell engager or CAR-T cell therapy

• Prior treatment with CD3 engaging bispecific antibodies

• Clinically significant cardiovascular diseases

• Active clinically significant infection (bacterial, viral, fungal, mycobacteria, orother)

• On supplemental oxygen

• Any medical condition or clinical laboratory abnormality likely to interfere withassessment of safety or efficacy of study treatment